Kelso Pharma, the high-growth specialty pharmaceuticals business, announces that Italian-based Velit Biopharma, acquired in November 2023, will trade as ‘Kelso Pharma Italy’ from today (21 October 2025), as the business gears up for further growth across European markets.
The rebranding of Velit Biopharma to Kelso Pharma Italy is a natural next step in the growth story of the business and demonstrates the support from shareholders and the parent company, Kelso Pharma Group.
Since joining the Kelso Pharma group of companies, Kelso Pharma Italy has become increasingly aligned with the Kelso Pharma focus on innovative, niche and complex medicines that deliver benefits to patients and value to healthcare systems. The company recently hosted its annual all-company meeting in Edinburgh, Scotland, highlighting major successes for the business in 2025 and planning ahead for a busy year of further growth in 2026.
Apposite Capital-backed Kelso Pharma is focused on bringing innovative, value-added, specialty medicines to international healthcare markets, providing products that improve the lives of patients in a cost-effective and ethical manner. The company is growing through a blend of company and product acquisitions, partnerships and organic growth internationally. UK-based, its assets currently consist of Stirling Anglian Pharmaceuticals; Kelso Pharma Italy (formerly Velit Biopharma); and ALTURiX.
Kelso Pharma Italy General Manager, Giovanni Mauri, said:
“This is a proud day for everyone across the Kelso Pharma Group. Since joining the Kelso Pharma team in late 2023, our Italian based team has gone from strength to strength.
“We are aligned in our mission to support patients and bring value to healthcare systems across Europe. Our team will be at CPHI Worldwide in Frankfurt next week, as we continue to drive forward our growth as Kelso Pharma Italy.”
Commenting on the change, Kelso Pharma CEO, Dr. Tom Stratford, said:
“Kelso Pharma Italy is an integral and exciting part of our business, driven by a talented and committed team. As we continue to grow and explore further expansion opportunities across Europe to support patients, Kelso Pharma Italy offers a unique opportunity to help accelerate that growth.”
